Ye, Dan, Wei Zhou, and Hon-Chi Lee. Activation of rat mesenteric arterial KATP channels by 11,12-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol 288: H358 -H364, 2005. First published August 26, 2004; doi:10.1152/ajpheart.00423.2004.-Epoxyeicosatrienoic acids (EETs), the cytochrome P-450 epoxygenase metabolites of arachidonic acid, are candidates of endothelium-derived hyperpolarizing factors. We have previously reported that EETs are potent activators of cardiac ATP-sensitive K ϩ (KATP) channels, but their effects on the vascular KATP channels are unknown. With the use of whole cell patch-clamp techniques with 0.1 mM ATP in the pipette and holding at Ϫ60 mV, freshly isolated smooth muscle cells from rat mesenteric arteries had small glibenclamide-sensitive currents at baseline (13.1 Ϯ 3.9 pA, n ϭ 5) that showed a 7.2-fold activation by 10 M pinacidil (94.1 Ϯ 21.9 pA, n ϭ 7, P Ͻ 0.05). 11,12-EET dose dependently activated the KATP current with an apparent EC50 of 87 nM. Activation of the KATP channels by 500 nM 11,12-EET was inhibited by inclusion of the PKA inhibitor peptide (5 M) but not by the inclusion of the PKC inhibitor peptide (100 M) in the pipette solution. These results were corroborated by vasoreactivity studies. 11,12-EET produced dose-dependent vasorelaxation in isolated small mesenteric arteries, and this effect was reduced by 50% with glibenclamide (1 M) preincubation. The 11,12-EET effects on vasorelaxation were also significantly attenuated by preincubation with cellpermeant PKA inhibitor myristoylated PKI(14 -22), and, in the presence of PKA inhibitor, glibenclamide had no additional effects. These results suggest that 11,12-EET is a potent activator of the vascular KATP channels, and its effects are dependent on PKA activities. Ϫ8 M. EETs activate cardiac K ATP channels directly, without the presence of second messengers, by reducing the channel sensitivity to ATP (17). EET effects are highly specific; neither arachidonic acid, its precursor, nor dihydroxyeicosatrienoic acid (its hydrolase metabolite) had any effect on K ATP channel activation. Furthermore, the effects of EET are stereospecific, and the epoxide functional group is the critical structural determinant that is required for K ATP channel activation (19). However, the role of EET in modulating the vascular K ATP channels is unknown. In this study, we examined the effects of 11,12-EET on K ATP channel activities in isolated smooth muscle cells from small mesenteric arteries in the rat. We found that 11,12-EET potently activates the vascular K ATP channels, but its effects are mediated through PKA-dependent mechanisms. These results were further corroborated by vasoreactivity experiments showing that 11,12-EET produces potent vasorelaxation in isolated mesenteric arteries that are significantly inhibited by the K ATP channel inhibitor glibenclamide and by PKA inhibition. These findings suggest that EETs could be important endogenous vascular K ATP channel activators and may play an integral role in vascular tone regulation.
ϩ (BK Ca ) channels, and are endothelium-derived hyperpolarizing factors (EDHFs) (4, 5, 23, 42) . In addition, EETs have been shown to inhibit the cardiac Na ϩ channels (14) , modulate cardiac L-type Ca 2ϩ channels (6, 34) , inhibit the cloned human T-type Ca 2ϩ channel (39) , and inhibit the tracheal Cl Ϫ channel (27) . Recently, we found that EETs are potent activators of the cardiac ATP-sensitive K ϩ (K ATP ) channels (17) with EC 50 values of 10 Ϫ8 M. EETs activate cardiac K ATP channels directly, without the presence of second messengers, by reducing the channel sensitivity to ATP (17) . EET effects are highly specific; neither arachidonic acid, its precursor, nor dihydroxyeicosatrienoic acid (its hydrolase metabolite) had any effect on K ATP channel activation. Furthermore, the effects of EET are stereospecific, and the epoxide functional group is the critical structural determinant that is required for K ATP channel activation (19) . However, the role of EET in modulating the vascular K ATP channels is unknown. In this study, we examined the effects of 11,12-EET on K ATP channel activities in isolated smooth muscle cells from small mesenteric arteries in the rat. We found that 11,12-EET potently activates the vascular K ATP channels, but its effects are mediated through PKA-dependent mechanisms. These results were further corroborated by vasoreactivity experiments showing that 11,12-EET produces potent vasorelaxation in isolated mesenteric arteries that are significantly inhibited by the K ATP channel inhibitor glibenclamide and by PKA inhibition. These findings suggest that EETs could be important endogenous vascular K ATP channel activators and may play an integral role in vascular tone regulation.
MATERIALS AND METHODS

Animals and isolation of arterial smooth muscle cells from rat small mesenteric arteries.
The use of animals and the procedures involved with tissue isolation were approved by the Animal Care and Use Committee at the Mayo Clinic (Rochester, MN). Single vascular smooth muscle cells were prepared as previously described (36) . Briefly, male Sprague-Dawley rats (200 -250 g body wt) were anesthetized with pentobarbital (100 mg/kg ip). The bowels and mesenteries were rapidly excised and placed in Krebs solution, which contained (in mM) 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH 2PO4, 25 NaHCO3, and 11.1 dextrose. The third-and fourthordered branches (100 -250 m in intraluminal diameter) of mesenteric arteries were carefully dissected and isolated free of surrounding connective tissue under a dissection microscope. The small arteries were then placed in 1 ml of physiological saline solution containing (in mM) 145 NaCl, 4.0 KCl, 0.05 CaCl 2, 1.0 MgCl2 10.0 HEPES, and 10.0 glucose, pH 7.2 with 0.1% BSA at room temperature for 10 min, followed by treatment with 1.75 mg of papain (11.9 U/mg) and 1.25 mg of dithiothreitol in 1 ml of saline solution at 37°C for 10 min. The vessels were further digested with 1.25 mg of collagenase (CLS-2, 360 U/mg) and 1.25 mg of trypsin inhibitor in 1 ml of saline solution at 37°C for 10 min, washed three times with 1.0-ml aliquots of saline solutions, and then gently triturated with a fire-polished glass pipette until they were completely dissociated. The resulting smooth muscle cell suspension was stored at 4°C and used within 8 h.
Whole cell patch-clamp recordings. Whole cell currents were recorded from single smooth muscle cells using patch-clamp techniques as previously described (13, 14) . Isolated smooth muscle cells were placed in a recording chamber on the stage of an inverted microscope with an extracellular bath solution that contained (in mM) 134 NaCl, 6 KCl, 1 MgCl 2, 0.1 CaCl2, 10 HEPES, and 10 glucose, pH 7.4. Cells were superfused with a 140 mM high-K ϩ bath solution, made by substituting NaCl with KCl in the above solution, at 1-2 ml/min, and solution exchanges were complete within 30 -60 s.
Whole cell KATP currents were recorded with a pipette solution that contained (in mM) 110 KCl, 30 KOH, 10 HEPES, 10 EGTA, 1 MgCl 2, 1 CaCl2, 0.1 Na2ATP, 0.1 Na2ADP, and 0.5 Na2GTP, pH 7.4, using an Axopatch 200 integrating amplifier (Axon Instruments; Foster City, CA), filtered at 1 kHz and sampled at 2 kHz. Pipette resistance ranged from 3 to 5 M⍀, and seal resistance was Ͼ10 G⍀. pCLAMP 8.0 software (Axon) was used for generating voltage-clamp protocols and for the acquisition and analysis of K ATP current. All cellular electrophysiology experiments were performed at room temperature (21-23°C). To minimize the activity of voltage-dependent K ϩ (delayed rectifiers) channels, most of the experiments were performed at a negative holding potential of Ϫ60 mV and extracellular K ϩ at 140 mM to elicit a substantial inward driving force for K ϩ (13) . To minimize the activity of BKCa channels, intracellular Ca 2ϩ was buffered by EGTA to low levels (ϳ20 nM). In addition, 100 nM iberiotoxin (IBTX) was present in the bath solution to block the BK Ca channel activities that could be activated by EET (18) . Glibenclamidesensitive K ϩ currents were determined and were referred to as KATP currents.
Vasoreactivity measurements. Vasoreactivity of isolated small mesenteric arteries (100 -250 m in diameter) was determined by videomicroscopy as previously described (36, 40) . Isolated small mesenteric arteries (1-2 mm in length) were transferred to a vessel chamber filled with Krebs solution and were equilibrated for at least 30 min at 37°C before the start of the experiment. The arteries were mounted and secured between two borosilicate glass micropipettes (30-m-diameter tips) with a 10-O ophthalmic suture. The lumen of the vessel was filled with Krebs solution through the micropipettes and maintained at a constant pressure (no flow) of 60 mmHg. The vessel chamber was transferred to the stage of an inverted microscope coupled to a video measurement system (VIA-100, Boeckeler Instruments), which was equipped with a video camera, monitor, and calibrated video calipers for visualization and recording of the intraluminal diameter. All compounds were added to the circulating bath, and the cumulative dose response was determined at 3-to 5-min intervals between doses. Vessels were constricted to about 40% of baseline diameter using endothelin-1. These vessels contained intact endothelium, and 10 Ϫ4 M acetylcholine produced 82.1 Ϯ 4.7% vasorelaxation. The effects of 11,12-EET in relaxing these vessels were examined over the concentration range of 1 ϫ 10 Ϫ10 to 1 ϫ 10 Ϫ6 M. Vessels were discarded if they failed to produce an 85% relaxation with 1 ϫ 10 Ϫ4 M sodium nitroprusside or failed to produce a 30% constriction with 60 mM KCl.
Materials. 11,12-EET was obtained from Cayman Chemical (Ann Arbor, MI), solubilized in ethanol as a 5 mM stock, and stored at Ϫ80°C. The PKA inhibitor peptide myristoylated PKI (14 -22) amide and the PKC inhibitor peptide myristoylated PKC(20 -28) were obtained from BioMol (Plymouth Meeting, PA). Pinacidil, glibenclamide, dibutyryl cAMP, enzymes, and the rest of the chemicals were obtained from Sigma Chemical (St. Louis, MO). Pinacidil was solubilized in DMSO as a 10 mM stock. The rest of the chemicals were solubilized in water.
Statistical analysis. All data are expressed as means Ϯ SE. A paired Student's t-test was used to compare data obtained before and after intervention. One-way ANOVA was used to analyze data from multiple groups, and pairwise comparisons among the groups were performed using a post hoc Tukey test. A statistically significant difference is defined as P Ͻ 0.05.
RESULTS
11,12-EET is a potent activator of the mesenteric K ATP channels. Mesenteric vascular smooth muscle cells exhibit very little glibenclamide-sensitive K
ϩ currents at baseline. With 0.1 mM ATP in the pipette, at a holding membrane potential of Ϫ60 mV and 140 mM extracellular K ϩ , the K ATP current amplitude was 13.1 Ϯ 3.9 pA (n ϭ 5). However, 10 M pinacidil produced a 7.2-fold activation of these currents (94.1 Ϯ 21.9 pA, n ϭ 7, P Ͻ 0.05 vs. control; Fig. 1, A and B) .
In studying the effects of 11,12-EET on K ATP channels in vascular smooth muscle cells, we found that there was consistently an inward current being activated by 11,12-EET that would interfere with K ATP current measurements even at Ϫ60 mV (data not shown). This current could be blocked by 100 nM IBTX in the bath solution and represents the activated BK Ca currents by 11,12-EET from a hyperpolarization shift in the current-voltage relationship (18) . Hence, all experiments involving 11,12-EET were performed with 100 nM IBTX in the bath solution.
11,12-EET dose dependently activated K ATP currents in mesenteric smooth muscle cells. 11,12-EET (5 nM) had no effect (10.0 Ϯ 1.0 pA, n ϭ 5), but K ATP currents were increased by 44% with 50 nM 11,12-EET to 18.9 Ϯ 2.6 pA (n ϭ 8), by 181% with 500 nM 11,12-EET to 36.8 Ϯ 6.2 pA (n ϭ 7, P Ͻ 0.05 vs. control), and by 208% with 5 M 11,12-EET to 40.4 Ϯ 8.1 pA (n ϭ 7, P Ͻ 0.02 vs. control; Fig.  1, C and D) . The dose-response relationship fitted with a Hill equation showed an EC 50 of 87 nM and a Hill coefficient of 1.6 (Fig. 1D) . These results indicate that 11,12-EET is a potent activator of mesenteric K ATP channels with an EC 50 in a similar concentration range to that for the cardiac K ATP channels (18) . Although 11,12-EET is not as efficacious as pinacidil in K ATP channel activation, it is capable of producing 43% of the peak pinacidil effect.
The effects of 5 M 11,12-EET on the current-voltage relationship of K ATP currents are shown in Fig. 2 . In the presence of symmetrical K ϩ at 140 mM and 100 nM IBTX in the bath, currents were elicited with a holding potential of 0 mV and pulsing from Ϫ100 to 40 mV in increments of 10 mV. The evoked currents were significantly activated by 11,12-EET, and the EET effects were blocked by glibenclamide (Fig.  2, A-C) . Group results are shown in Fig. 2D , and 11,12-EET produced significant activation of K ATP currents at all negative potentials (n ϭ 7, P Ͻ 0.05).
11,12-EET effects are mediated through PKA-dependent mechanisms. To further investigate the mechanism of K ATP channel activation by 11,12-EET, we examined the role of second messenger systems in mediating these effects. The K ATP channel is known to be modulated by protein kinases including PKA-and PKC-dependent mechanisms (10, 11, 13, 15, 26, 33, 37) . Application of membrane-permeable dibutyryl cAMP at 0.5 mM resulted in a modest increase in K ATP currents and did not prevent subsequent current increase by 500 nM 11,12-EET (Fig. 3, A and B) . However, exposure to 1 mM dibutyryl cAMP produced a much more robust K ATP current response, to levels similar to those induced by 500 nM 11,12-EET. Subsequent exposure to 500 nM 11,12-EET produced no further K ATP current increase (Fig. 3, C and D) , suggesting that the stimulatory effects of 11,12-EET on K ATP channels might be cAMP mediated.
These results were confirmed by experiments with the PKA inhibitor peptide myristoylated PKI (14 -22) , included in the pipette solution for internal cellular dialysis. In the presence of 5 M PKI (14 -22) , the ability of 500 nM 11,12-EET to activate K ATP currents was significantly attenuated, producing only 43 Ϯ 30% of current increase (5.2 Ϯ 2.3 pA increase, n ϭ 8) compared with a 435 Ϯ 116% of current increase under control conditions (31.5 Ϯ 5.3 pA increase, n ϭ 7, P Ͻ 0.005).
In contrast, with 100 M PKC inhibitor peptide myristoylated PKC (20 -28) in the pipette solution, no inhibition of the 11,12-EET effects was observed, with 870 Ϯ 326% of K ATP current increase (68.8 Ϯ 22.8 pA increase, n ϭ 4, P ϭ not significant vs. control; Fig. 4 ). These results indicate that activation of mesenteric K ATP channels by 11,12-EET is mediated through a PKA-dependent mechanism. Interestingly, the greater EET effect observed in the presence of PKC inhibitor peptides suggests that there could be baseline PKC-mediated inhibition on vascular K ATP channels.
All four EET regioisomers are effective activators of the K ATP channels. To determine and compare the effects of the four EET regioisomers on K ATP channel activation in vascular smooth muscle cells, we measured the increase in glibenclamide-sensitive K ϩ currents after exposure to 5 M 5,6-, 8,9-, 11,12-, or 14,15-EET. Currents were elicited with a holding potential of 0 mV and a testing potential of Ϫ100 mV. We found that all four EET regioisomers were effective activators of vascular K ATP channels. Compared with controls that were exposed to vehicle only (19.0 Ϯ 7.9 pA, n ϭ 5), K ATP currents were significantly enhanced by 5,6-EET (86.2 Ϯ 15.8 pA, n ϭ 5, P Ͻ 0.005 vs. control), 8,9-EET (124.9 Ϯ 34.7 pA, n ϭ 5, P Ͻ 0.02 vs. control), 11,12-EET (100.4 Ϯ 23.7 pA, n ϭ 7, P Ͻ 0.02 vs. control), and 14,15-EET (140.5 Ϯ 35.5 pA, n ϭ 5, P ϭ 0.01 vs. control). The four EET regioisomers (5 M) produced a similar level of stimulation on vascular K ATP currents. In addition, these effects were similar to those attained by 10 M isoproterenol (108.4 Ϯ 11.3 pA, n ϭ 5, P Ͻ 0.001 vs. control), suggesting that K ATP channel activation by EET is comparable to that mediated by ␤-adrenergic stimulation (Fig. 5) .
Vasorelaxation of small mesenteric arteries by 11,12-EET is mediated through K ATP channel activation. To further determine the physiological relevance of vascular K ATP channel activation by EET, we examined the ionic mechanisms of mesenteric vasorelaxation by 11,12-EET. 11,12-EET produced potent dose-dependent vasorelaxation of small mesenteric arteries with 3.8 Ϯ 0.3% relaxation at 10 Ϫ10 M, 10.1 Ϯ 1.6% relaxation at 10 Ϫ9 M, 22.2 Ϯ 2.3% relaxation at 10 Ϫ8 M, 37.2 Ϯ 2.6% relaxation at 10 Ϫ7 M, and 49.4 Ϯ 2.6% relaxation at 10 Ϫ6 M (n ϭ 5). These values were similar to those reported in rat mesenteric arteries (22) and in bovine coronary arteries (4). After incubation with 1 M glibenclamide for 30 min, the vasorelaxation effects of 11,12-EET in small mesenteric arteries were significantly attenuated at all doses, with only 10.6 Ϯ 2.0% relaxation at 10 Ϫ8 M and 27.1 Ϯ 2.3% relaxation at 10 Ϫ6 M (n ϭ 6, P Ͻ 0.05 vs. control for all doses) (Fig. 6) . These results indicate that one-half of the EET vasorelaxation effects in rat small mesenteric arteries are mediated through activation of K ATP channels. After incubation with 100 nM IBTX for 30 . Controls were superfused with buffer containing no EET (n ϭ 5). Each cell was exposed to one dose of EET, and control cells were exposed to vehicle. Data are presented as means Ϯ SE, and the continuous line represents the best fit by a Hill equation. The apparent EC50 for 11,12-EET was 87 nM, and the Hill coefficient was 1.6. min, the vasorelaxation effects of 11,12-EET were also significantly attenuated at all doses, with only 7.0 Ϯ 1.4% relaxation at 10 Ϫ8 M and 23.8 Ϯ 1.8% relaxation at 10 Ϫ6 M (n ϭ 5, P Ͻ 0.05 vs. control for all doses), suggesting that the BK Ca channels also contribute significantly to EET-mediated vasorelaxation in these vessels. Preincubation with both IBTX and glibenclamide had an additive effect, resulting in almost complete inhibition of EET vasorelaxation effects (Fig. 6 ).
To determine whether EET-mediated vasorelaxation is dependent on PKA activity, we preincubated isolated mesenteric vessels with cell-permeable myristoylated PKI(14 -22) (5 M) for 45 min and found that the vasodilatory effects of 11,12-EET were significantly attenuated at all doses, with 8.8 Ϯ 1.2% relaxation at 10 Ϫ8 M and 28.9 Ϯ 2.3% relaxation at 10 Ϫ6 M (n ϭ 6, P Ͻ 0.05 vs. control at all doses). Preincubation with both PKA inhibitor and glibenclamide had no additional dim- A: whole cell current recording showing minimal current activation by 0.5 mM dibutyryl cAMP, whereas subsequent exposure to 500 nM 11,12-EET resulted in significant activation of glibenclamide-sensitive (10 M) currents. B: group data showing the KATP current at baseline, after exposure to 0.5 mM db-cAMP, and after exposure to 0.5 mM db-cAMP ϩ 500 nM 11,12-EET (n ϭ 7, *P Ͻ 0.05 vs. baseline and **P Ͻ 0.005 vs. baseline). C: whole cell K ϩ current recording showing activation by 1 mM db-cAMP and subsequent exposure to 500 nM 11,12-EET showed no further current activation. D: group data showing the KATP current densities at baseline, after exposure to 1 mM db-cAMP, and after exposure to 1 mM dbcAMP ϩ 500 nM 11,12-EET (n ϭ 7, **P Ͻ 0.005 vs. baseline).
inution of the EET effects, with 8.9 Ϯ 1.4% relaxation at 10 Ϫ8 M and 27.3 Ϯ 2.4% relaxation at 10 Ϫ6 M (n ϭ 6, P Ͻ 0.05 vs. control for all doses, P ϭ not significant vs. with only PKA inhibitor preincubation) (Fig. 6) . These results indicate that the PKA signaling cascade produces the vasorelaxation effects of 11,12-EET in the small mesenteric arteries and that the vascular K ATP channels are dependent on this mechanism in mediating its vasorelaxation effects.
DISCUSSION
The major findings in this study include the following. First, 11,12-EET is a potent activator of mesenteric K ATP channels, with an EC 50 of 87 nM, similar to that reported in cardiac K ATP channels. Second, all four EET regioisomers are effective activators of the vascular K ATP channels. Third, in contrast to EET activation of cardiac K ATP channels, which does not require any cytosolic second messengers, activation of mesenteric K ATP channels by 11,12-EET is mediated through PKAdependent mechanisms. Finally, activation of K ATP channels in small mesenteric arteries by EET is a physiologically important mechanism, accounting for 50% of the EET vasorelaxation effects.
K ATP channels are ubiquitous and play a unique role in coupling the cellular metabolic state to excitability (28, 30, 37) . Cardiac K ATP channels have been shown to modulate the cardiac action potential and contractility (31) and protect the heart against ischemia and stress (32, 41). Vascular K ATP channels are thought to play important roles in the vascular responses to a variety of pharmacological and endogenous vasodilators (3, 26) . Recently, studies using mice with knockout of the Kir6.1 gene, which is thought to encode vascular K ATP channels, produced the surprising finding that these animals develop spontaneous coronary spasm, leading to severe lethal atrioventricular block and sudden death (21) . These findings provided further insight into the critical role that vascular K ATP channels play in the regulation of vascular tone. The vascular responses to pharmacological vasodilators such as pinacidil are well defined. However, understanding of the endogenous mediators that activate these important channels has remained incomplete.
Previous studies from different laboratories have shown that EETs function as EDHFs in the coronary and other circulations (4, 5, 8) . EETs are potent activators of vascular BK Ca channels, producing membrane hyperpolarization, leading to vasorelaxation (4, 23, 40) . The role of EETs on vascular K ATP channel activation has not been studied directly, although Fukao et al. (9) reported that 11,12-EET-induced smooth muscle hyperpo- larization in isolated rat mesenteric arteries was blocked by glibenclamide, suggesting that K ATP channels were involved. We have recently reported that EETs are potent activators of cardiac K ATP channels (17, 19) . EETs markedly reduce the channel sensitivity to ATP, allowing these channels to open even in the presence of physiological concentrations of intracellular ATP (mM range). EETs increase K ATP channel opening probability, increase channel open dwell times, reduce channel closed times, and eliminate the long closed state, leading to significant hyperpolarization of resting membrane potential in cardiac myocytes (17) . In addition, the effects of EETs are stereospecific; only the 11(S),12(R)-EET enantiomer could activate cardiac K ATP channels and produce resting potential hyperpolarization, with the 11(R),12(S)-EET enantiomer being totally inactive (19) . These observations were made in inside-out patches, suggesting a direct EET effect on the channel without the requirement of diffusible second messengers. In the present study, we found that activation of mesenteric K ATP channels by 11,12-EET is mediated by a PKAdependent mechanism, underscoring the differences in pharmacological regulation between the cardiac and vascular channel isoforms. Indeed, the functional cardiac K ATP channel is encoded by the SUR2A and Kir6.2 subunits, whereas the vascular channel is formed by the coupling of SUR2B and Kir6.1 subunits, and they have inherent differences in channel unitary conductance as well as in the sensitivity to nucleotide diphosphates and to ATP (1, 26, 29, 37) . PKA has not been found to be an obligatory step in mediating the EET regulation of ion channels. Activation of BK Ca channels by EETs in vascular smooth muscles is not cAMP dependent (4), and cardiac Na ϩ channels are inhibited by EETs through a "modulated receptor" mechanism that is not cAMP mediated (14) . However, EETs have been shown to activate cardiac L-type Ca 2ϩ channels through cAMP-dependent mechanisms (34), although the mechanism through which EETs produce an increase in cAMP level is not clear, and evidence supporting the presence of a definitive plasmalemmal EET receptor has been elusive. With the use of the N-methylsulfonimide analog of 11,12-EET, which resists esterification and ␤-oxidation, Imig et al. (12) reported that afferent arteriolar vasodilation by this EET analog was PKA dependent. Vasodilation produced by 11,12-EET in small mesenteric arteries may also involve a similar mechanism, which in turn activates K ATP channels in the vascular smooth muscle cells, producing membrane hyperpolarization and vasorelaxation.
Activities of the K ATP channels have been shown to be modulated by PKA-and PKC-mediated phosphorylation (10, 11, 13, 15, 26, 37) . The effects of PKC appear to be stimulatory on cardiac K ATP channels (11, 15) but inhibitory on vascular K ATP channels (7, 10, 13) . In contrast, the effects of PKA on K ATP channels have been uniformly stimulatory (16, 37) . Our observations that 11,12-EET activates mesenteric K ATP channels with an EC 50 of 87 nM and that 500 nM 11,12-EET is capable of producing 43% of the peak effect of 10 M pinacidil indicate that 11,12-EET could be an important endogenous regulator of vascular K ATP channel activity. This mechanism of vasodilation should become even more important during ischemia or hypoxia when production of EET is enhanced and intracellular ATP is depleted (25) . Indeed, overexpression of cytochrome P-450 CYP2J2 has been shown to protect against hypoxia-reoxygenation injury in cultured endothelial cells (35) , and neuroprotection by experimental transient ischemic attacks is linked to the upregulation of cytochrome P-450 2C11 (2). In addition, Kir6.2 knockout mice have lost the cardioprotection effects of ischemic preconditioning (32) . Recently, hypoxia-induced vasodilation in human coronary arterioles mediated by K ATP opening was found to be impaired in diabetes (24) . Such findings suggest that activation of vascular K ATP channels by EETs could serve as an important protective mechanism for the cardiovascular system against ischemic and metabolic insults.
